

Attorney for Applicants
Sara D. Vinarov, Reg. No. 48,524
TEL 608-251-5000
FAX 608-251-9166

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Alan D. Attie
Jonathan P. Stoehr
Kathryn L. Schueler
Susanne Michelle Clee

Date: January 21, 2008

Serial No.: 10/655,915

Group Art Unit: 1634

Filed: 09/05/2003

Examiner: Jehanne Souaya Sitton

Title: TYPE 2 DIABETES SUSCEPTIBILITY GENES File No.: 960296.99080

Confirmation No.: 8862

DECLARATION OF SUSANNE MICHELLE CLEE
Under 37 CFR 1.132

Commissioner for Patents
P O Box 1450
Alexandria, VA 22313-1450

Dear Sir:

I, Susanne Michelle Clee, on oath declare and sayeth that:

1. I am the same Susanne Michelle Clee who is a named co-inventor on the above-identified patent application. I make this declaration in support of that patent application. I am currently employed by the University of British Columbia as an Assistant Professor in the Department of Cellular and Physiological Sciences. I have worked as a scientist for 12 years specializing in the genetics of complex diseases. I have published extensively in this area. A copy of my *Curriculum Vitae* is attached as Exhibit A.

2. I have reviewed the above-identified application and understand the nature and scope of the invention claimed therein. I have also reviewed the Office Action issued by the U.S. Patent and Trademark Office (USPTO) on July 31, 2007 for this application. I understand that currently Claims 1-3, and 12 stand rejected as failing to comply with the USPTO's enablement and written description requirements. I also understand that these rejections are largely due to the fact that Table 1, pg. 4, [00018] of the application contains an inadvertent

numbering error in the 1st row, 4th column ("position in protein"). An attempt was made to correct Table 1 in previous responses, however, the USPTO issued a "new matter" rejection asserting that the numbering correction was not supported by the original application as filed. I disagree with this rejection.

3. I believe that the numbering error, notably at amino acid position 52 in Table 1 does not constitute new matter. I also believe that not only would one of ordinary skill in this art recognize the existence of the error based on the specification as a whole, but one would also recognize the appropriate correction. Thus, correction of the amino acid position in the 1st row, 4th column of Table 1 from "50" to "52", which corresponds to nucleotide position 172 in the cDNA would have been immediately obvious to one of ordinary skill in the art at the time of filing.

4. As support for this belief, I submit that the following information was provided in the specification at the time of filing:

a) Mouse SorCS1 nucleotide (nt) sequence is disclosed as GenBank Accession No. AF195056 (see specification pg. 6, paragraph 25, last line). A copy of GenBank Accession No. AF195056 is provided herewith as Exhibit B. Mouse SorCS1 nucleotide sequence shows that the 1st initiation codon, ATG (Met) corresponds to nucleotides 18-20. The 5'untranslated region (UTR) is 17 nucleotides in length. From the 1st nucleotide in the 1st amino acid ATG (Met) to nucleotide 172 (location of the substitution, the 2nd nucleotide of the Thr at position 52), there are 155 nucleotides (172nt - 17nt in 5'UTR = 155nts).

b) Human SorCS1 nucleotide sequence is disclosed as GenBank Accession No. NM_052918 and amino acid sequence as GenBank Accession No. NP_443150 (see specification pg. 5, paragraph 19, and enclosed Exhibit C).

c) The Sequence Listing in the specification includes SEQ ID NOs. 3 and 4.

i) SEQ ID NO. 3 is the human SorSC1 nucleotide sequence, which discloses that the 5'UTR is 8 nucleotides in length. The 1st amino acid is a Met and it corresponds to nucleotides 9-11 (ATG). 155 nucleotides from the 1st

nucleotide in the 1st amino acid (Met) is the 2nd nucleotide in the Thr at position 52, which corresponds to position 163 in the human cDNA (155 nt + 8 nt in 5'UTR = 163 nts).

ii) SEQ ID NO. 4 is the human SorSC1 amino acid sequence, which discloses a Thr (ACC) at position 52, but not position 50 (Ala).

d) Figure 2A-H in specification provides an amino acid sequence alignment for mouse SorCS1a, b, c (SEQ ID NOs: 11-13) and human SorCS1 (SEQ ID NO: 14). For mouse and human SorSC1 amino acid sequences, there is a T (Thr) at position 52. As shown in SEQ ID NO. 4 and Figure 2, in human SorCS1 there is an Ala at amino acid 50, not a Thr.

5. Based on the above information provided in the specification, one of skill in the art would readily recognize that the published mouse 5'UTR is 17 nucleotides in length and the published human 5'UTR is 8 nucleotides in length. The difference in the untranslated regions of the two species is 9 nucleotides. The published mouse and human coding sequences show that the number of nucleotides from the first nucleotide (A, adenine) of the first amino acid (Met) to the substituted nucleotide in the amino acid in question must be 155 nucleotides. Due to the different lengths of the 5'UTR, in mouse, amino acid position 52 corresponds to nucleotides 171, 172 and 173 (ACC). In human, amino acid position 52 corresponds to nucleotides 162, 163 and 164 (ACC). (Underlining shows the corresponding change in the nucleotide).

6. Based on the published mouse SorSC1 sequence, the 5'UTR is 17 nucleotides in length, and the total length from the beginning of the 5'UTR to the substituted nucleotide in the amino acid in question is 172 nucleotides long. Therefore, the coding sequence from the 1st nucleotide of the first amino acid to the substituted nucleotide in the amino acid in question is 155 nucleotides (172nt – 17nt).

7. Since an amino acid is made up of 3 nucleotides, 155 nucleotides would equal 51 amino acids (153 nt) plus 2 nucleotides. These 2 nucleotides are the first 2 nucleotides of the amino acid at position 52 of the published mouse SorSC1 sequence.

8. I submit that in the first row, first column of Table 1, the number 172 is the substituted nucleotide position in the mouse SorSC1 sequence. The C to T in the 2nd and 3rd column, first row of Table 1, denote the substitution in the 2nd nucleotide of the amino acid that is the subject matter of the pending claims. The number 50 in column 4, first row of Table 1 denotes the location of the amino acid that contains the above mentioned substitution in the 2nd nucleotide. The coding sequence from the 1st nucleotide of the 1st amino acid to the substituted nucleotide in the amino acid in question (number 50) is 149 nucleotides, not the 155 nucleotides dictated by a mutation at nucleotide 172.

9. One skilled in the art would immediately recognize that the number "50" as the position of the mutation in the mouse SorCS1 sequence is clearly wrong. This is because the published mouse SorSC1 sequence has a 5'UTR that is 17 nucleotide in length, and the total length from the beginning of the 5'UTR to the substituted nucleotide in the amino acid in question is 172 nucleotides long. In mouse, the number of SorSC1 nucleotides in the coding sequence from the 1st nucleotide of the 1st amino acid to the substituted nucleotide in the amino acid in question is 155 nucleotides. The difference between 149 and 155 is 6 nucleotides which would immediately alert one skilled in the art that the difference is 2 amino acids. Therefore, the amino acid in question should be 52 not 50.

10. Further, in the published human SorSC1 sequence, the 5'UTR is 8 nucleotides in length, and the total length from the beginning of the 5'UTR to the substituted nucleotide in the amino acid in question is 163 nucleotides long. The coding sequence from the 1st nucleotide of the 1st amino acid to the substituted nucleotide in the amino acid in question is still 155 nucleotides. This means that similar to the above analysis for the mouse SorSC1 sequence, the human SorCS1 sequence with 155 nucleotides in length equals 51 amino acids plus 2 nucleotides. These 2 nucleotides are the first 2 nucleotides of the amino acid at position 52 of the published human SorSC1 sequence. Like, the mouse SorSC1 analysis, one skilled in the art would immediately realize that in the human sequence the amino acid in question is also "52" not "50."

11. For the sake of argument, even if one skilled in the art were to use the number 50 in the first row, column 4 of Table 1, as the amino acid that contains the substitution in the 2nd

Application No.: 10/655,915

nucleotide, the coding sequence from the 1st nucleotide of the 1st amino acid to the substituted nucleotide in the amino acid in question would be 149 nucleotides. One skilled in the art would immediately recognize that the number "50" in Table 1 is a sequence error because 1) the published mouse SorSC1 sequence has a 5'UTR that is 17 nucleotides in length, and 2) the total length from the beginning of the 5'UTR to the substituted nucleotide in the amino acid in question is 172 nucleotides long. Therefore, the coding sequence from the 1st nucleotide of the 1st amino acid to the substituted nucleotide in the amino acid in question is 155 nucleotides.

12. The difference in the number of nucleotides between 149 and 155 is 6. One skilled in the art would immediately recognize this difference of 6 nucleotides translates into a difference of 2 amino acids. This would make the amino acid position in table 1, which is in question, "52" not "50." Therefore, I believe that correction of the amino acid position in the 1st row, 4th column of Table 1 from "50" to "52" corresponding to nucleotide position 172 in the mouse SorCS1 cDNA would have been immediately obvious to one of ordinary skill in the art at the time of filing.

13. I hereby declare that all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further, that these statements are made with knowledge that willful false statements, and the like so made, are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Further declarant sayeth not.

Dated: January 21, 2008



Susanne Michelle Clee

THE UNIVERSITY OF BRITISH COLUMBIA
Curriculum Vitae for Faculty Members

Date:

Initials:

1. **SURNAME:** CLEE **FIRST NAME:** Susanne
MIDDLE NAME(S): Michelle
2. **DEPARTMENT/SCHOOL:** Department of Cellular and Physiological Sciences
3. **FACULTY:** Medicine
4. **PRESENT RANK:** Assistant Professor **SINCE:** August 2007
5. **POST-SECONDARY EDUCATION**

University or Institution	Degree	Subject Area	Dates
University of British Columbia, Canada	Ph.D.	Genetics	1995-2001
Simon Fraser University, Canada	B.Sc. (Hon)	Biochemistry	1990-1994

Title of Dissertation and Name of Supervisor

Lipoprotein lipase and the ATP binding cassette transporter ABCA1: Two genes regulating plasma high density lipoprotein cholesterol and triglyceride levels and risk of coronary artery disease.

Supervisor: Dr. Michael R. Hayden

Special Professional Qualifications


6. **EMPLOYMENT RECORD**

(a) *Prior to coming to UBC*

University, Company or Organization	Rank or Title	Dates
University of Wisconsin-Madison, Dept of Biochemistry	Assistant Scientist	7/2006-6/2007
University of Wisconsin-Madison, Dept of Biochemistry	Postdoctoral Fellow	9/2001-6/2006

(b) *At UBC*

Rank or Title	Dates
Assistant Professor	8/2007+



--	--

(c) *Date of granting of tenure at U.B.C.:*

7. LEAVES OF ABSENCE

University, Company or Organization at which Leave was taken	Type of Leave	Dates

8. TEACHING

(a) *Areas of special interest and accomplishments*

(b) *Courses Taught at UBC*

[illegible](c) *Graduate Students Supervised and/or Co-Supervised*[illegible]

--	--	--	--	--	--

(d) *Continuing Education Activities*

(e) *Visiting Lecturer (indicate university/organization and dates)*

(f) *Other*

9. SCHOLARLY AND PROFESSIONAL ACTIVITIES

(a) *Areas of special interest and accomplishments*

Genetics of metabolic diseases, in particular obesity and diabetes
Physiology of animal models of metabolic disease

(b) *Research or equivalent grants (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC))*

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)
American Heart Association	Scientist Development Grant: <i>Identification of the Modifier of Obese 1 (Moo1) obesity gene</i>	C	65,000	7/06-6/10	Susanne M Clee	
American Heart Association	Postdoctoral Fellowship	C	35,000 (yr1) 40,000 (yr2)	7/05-6/06	Susanne M Clee	
American Heart Association	Postdoctoral Fellowship	C	51,048	7/03-6/05	Susanne M Clee	

(c) *Research or equivalent contracts (indicate under COMP whether grants were obtained competitively (C) or non-competitively (NC)).*

Granting Agency	Subject	COMP	\$ Per Year	Year	Principal Investigator	Co-Investigator(s)

(d) *Invited Presentations*

1. **Clee S.M.** Genotyping strategies for fine-mapping a diabetes QTL. Wisconsin Symposium III. Madison, WI May 20-23, 2003.
2. **Clee S.M.**, Attie A.D. The BTBR *ob/ob* model of type II diabetes. New Genetic and Metabolic Insights into Animal Models of Diabetes. Bar Harbor ME June 17-21, 2003.
3. **Clee S.M.**, Attie A.D. New genes for type II diabetes from genetic and genomic studies in mice. Washington University Lipid and Diabetes Symposium, St. Louis MO, Apr. 21, 2005.
4. **Clee S.M.** Positional cloning of a type 2 diabetes susceptibility gene: SorCS1, Marshfield Clinic, Marshfield WI, Sept. 2006.
5. **Clee S.M.** Genetics of obesity and type 2 diabetes, CIHR New Principal Investigator Meeting, Jackson's Pt. ON, Nov. 2007.

(e) *Other Presentations (selected from abstracts, presenting author underlined)*

1. Pimstone S. N., Gagne E., **Clee S. M.**, Stein E. A., and Hayden M. R. Post Prandial Retinyl Palmitate Response Supports Evidence for a Functional Effect of the Asn291Ser Mutation in the Lipoprotein Lipase Gene. *Oral presentation*, 68th Scientific Sessions of the American Heart Association, Anaheim CA Nov 13-16, 1995. *Circulation* 92 (8, Suppl.) I493. Oct. 15, 1995.
2. Pimstone S. N., Hayden M. R., **Clee S. M.**, Bakker H. D., Kastelein J. J. P. and Defesche J. C. Familial Defective Apolipoprotein B: Evidence For a Milder Phenotype in Children. *Poster*, 66th Congress of the European Atherosclerosis Society, Florence Italy July 13-17, 1996.
3. **Clee S. M.**, Zhang H., Benlian P., Miao L., Bissada N., Shen G. X., Angel A., LeBoeuf R. C., and Hayden M. R. Lipoprotein Lipase Increases HDL Cholesterol Levels in Mice Expressing Cholesterol Ester Transfer Protein. *Oral presentation*, Pacific Northwest Lipid Club, Seattle WA, Oct. 11-12, 1996.
4. **Clee S. M.**, Zhang H., Benlian P., Miao L., Bissada N., Shen G. X., Angel A., LeBoeuf R. C., and Hayden M. R. Lipoprotein Lipase Increases HDL Cholesterol Levels in Mice Expressing Cholesterol Ester Transfer Protein. *Oral presentation*, 69th Scientific Sessions of the American Heart Association, New Orleans LA Nov 10-13, 1996. *Circulation* 1996 **94** (8, Suppl.): I399.
5. **Clee S. M.**, Ginzinger, D. G., Excoffon, K. J. D. A., Backus, R. C., Lewis, M. E. S., Jones, B., Rogers, Q. R., and Hayden M. R. Decreased Adipose Tissue and Tolerance of High Fat/High Cholesterol Feeding Despite Massive Hypertriglyceridemia in Cats Homozygous for LPL Deficiency. *Poster*, Enzymes, Receptors, and Drugs in Obesity and Atherosclerosis, Toronto, ON May 7-9, 1998. *Clinical Biochemistry* 1998 **31**:601.
6. **Clee, S. M.**, Bissada N., Miao F., Miao L., Steures P., Marais A. D., McManus J., McManus B., Henderson H. E., and Hayden M. R. Atherogenicity of Lipoprotein Lipase is Related to Its Site of Expression: *In Vivo* Evidence of Vessel Wall versus Plasma Effects. *Oral presentation*, Canadian Lipoprotein Conference, Muskoka ON. Oct. 16-19, 1998.
7. **Clee S. M.**, Wittekoek M. E., Loubser O., Collins J., Moll E., Pimstone S. N., Kastelein J. J. P. and Hayden M. R. Common Variants of Lipoprotein Lipase (LPL) Strongly Influence Levels of Lipids and Lipoproteins and Coronary Artery Disease (CAD) in Patients with Familial Hypercholesterolemia (FH). *Poster presentation*, Canadian Lipoprotein Conference, Muskoka ON. Oct. 16-19, 1998.
8. **Clee, S. M.**, Bissada N., Miao F., Miao L., Steures P., Marais A. D., McManus J., McManus B., Henderson H. E., and Hayden M. R. Atherogenicity of Lipoprotein Lipase is Related to Its Site of Expression: *In Vivo* Evidence of Vessel Wall versus Plasma Effects. *Poster presentation*, 71st Scientific Sessions of the American Heart Association, Dallas TX Nov. 8-11, 1998. *Circulation* 1998 **98**(17):I-531
9. Kastelein J. J. P., Wittekoek M. E., Loubser O., **Clee S. M.**, Collins J., Moll E., Pimstone S. N., and Hayden M. R. Common Variants of Lipoprotein Lipase (LPL) Strongly Influence Levels of Lipids and Lipoproteins and Coronary Artery Disease (CAD) in Patients with Familial Hypercholesterolemia (FH). *Oral presentation*, 71st Scientific Sessions of the American Heart Association, Dallas TX Nov. 8-11, 1998. *Circulation* 1998 **98**(17):I-739.
10. **Clee, S. M.**, Loubser O., Wittekoek M. E., Collins J., Pimstone S. N., Moll E., Kastelein J. J. P. and Hayden M. R. Common Variants of Lipoprotein Lipase (LPL) Strongly Influence Lipid Levels, Blood Pressure and

- Coronary Artery Disease in Patients with Familial Hypercholesterolemia. *Poster presentation*, Canadian Genetic Diseases Network Annual Scientific Meeting, Collingwood ON April 20-23, 1999.
11. **Clee, S. M.**, Marcil M., Brooks-Wilson A., Roomp K., Zhang L., Yu L., Collins J.A., van Dam M., Loubser O., Ouellette B.F.F., Sensen C. W., Fichter K., Mott S., Denis M., Pimstone S., Kastelein J.J.P., Genest J. Jr., Hayden M.R. Familial HDL deficiency with defective cholesterol efflux is caused by mutations in CERP (ABC1). *Oral presentation*, Canadian Lipoprotein Conference, Mont-Tremblant PQ Oct. 15-18, 1999
 12. **Brooks-Wilson A.**, Marcil M., **Clee S. M.**, Zhang L.-H., Roomp K., van Dam M.J., Yu L., Brewer C., Collins J.A., Molhuizen H.O.F., Ouellette B.F.F., Sensen C.W., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J.P., Genest J. Jr., Hayden M.R. Mutations in transportin (ABC1) in Tangier disease and familial HDL deficiency. *Oral presentation*, American Society of Human Genetics, San Francisco CA, Oct. 19-23, 1999. *American Journal of Human Genetics* 1999 65(4 suppl):A34.
 13. **Clee S. M.**, Loubser O., Collins J., Kastelein J. J. P., and Hayden M. R. The lipoprotein lipase S447X variant is associated with decreased systolic and diastolic blood pressure. *Poster presentation*, 72nd Scientific Sessions of the American Heart Association, Atlanta GA Nov. 7-10, 1999. *Circulation* 1999 100(18):I822.
 14. **Clee S.M.**, Zwarts K.Y., Roomp K., Collins J.A., Marcil M., van Dam M., Brooks-Wilson A., Genest J. Jr., Kastelein J.J.P., and Hayden M.R. HDL levels in ABCA1 heterozygotes are predicted by cholesterol efflux levels and are influenced by age. *Poster presentation*, American Society of Human Genetics 50th annual meeting, Philadelphia PA Oct 3-7, 2000. *American Journal of Human Genetics* 2000 67(4 Suppl 2):350.
 15. Molhuizen H.O.F., **Clee S.M.**, Zwiderman A.H., Engert J., Zwarts K.Y., Brooks-Wilson A., Hudson T., Jukema J.W., Kastelein J.J.P., and Hayden M.R. cSNP analysis of the ABCA1 gene: the R219K variant is associated with a blunted age-modulated increase in HDL cholesterol and decreased coronary artery disease (CAD). *Poster presentation*, American Society of Human Genetics 50th annual meeting, Philadelphia PA Oct 3-7, 2000. *American Journal of Human Genetics* 2000 67(4 Suppl 2):233.
 16. **Clee S.M.**, Molhuizen H.O.F., Zwiderman A.H., Engert J., Roomp K., Jukema J.W., Zwarts K.Y., Rieder M.J., Nickerson D.A., Hudson T., Kruglyak L., Brooks-Wilson A., Genest J. Jr., Kastelein J.J.P., and Hayden M.R. Complete cSNP analysis of the ABC1 gene and association of the R219K variant with altered lipoproteins and risk of CAD. *Oral presentation*, Canadian Lipoprotein Conference, White Rock BC Oct 22-29, 2000.
 17. **Wellington C.L.**, **Clee S.M.**, Kwok A., Marcil M., Singaraja R., Kastelein J.J.P., Genest J. Jr., and Hayden M.R. Upregulation of ABC1 protein by 9-cis-retinoic acid, 22-R-OH-cholesterol is inhibited by truncation mutations. *Poster presentation*, 25th Annual Canadian Lipoprotein Conference, White Rock BC Oct 22-29, 2000.
 18. **Clee S.M.**, Zwarts K.Y., Roomp K., Collins J.A., van Dam M., Marcil M., Brooks-Wilson A., Genest J. Jr., Kastelein J.J.P., and Hayden M.R. The age modulated phenotype in heterozygotes for mutations in ABC1 includes significantly decreased HDL, increased triglycerides and an increased frequency of coronary artery disease (CAD). *Oral presentation*, 73rd Scientific Sessions of the American Heart Association, New Orleans LA Nov. 12-15, 2000. *Circulation* 2000 102 (18):II-31.
 19. **Clee S.M.**, Molhuizen H.O.F., Zwiderman A.H., Engert J.C., Roomp K., Zwarts K.Y., Jukema J.W., Hudson T.J., Brooks-Wilson A., Kastelein J.J.P., and Hayden M.R. cSNPs within the ABC1 gene influence HDL cholesterol levels and risk of coronary artery disease (CAD). *Poster presentation*, 73rd Scientific Sessions of the American Heart Association, New Orleans LA Nov. 12-15, 2000. *Circulation* 2000 102 (18):II-278.
 20. **Clee S.M.**, Zwarts K.Y., Zwiderman A.H., Engert J.C., Roomp K., Jukema J.W., Hudson T.J., Brooks-Wilson A., Kastelein J.J.P., and **Hayden M.R.** ABCA1 regulatory variants influence CAD independent of effects on plasma lipid levels. *Oral presentation*, 74th Scientific Sessions of the American Heart Association, Anaheim CA Nov. 11-14, 2001. *Circulation* 2001 104 (17):2131. (unable to present due to illness)
 21. **Wellington C.L.**, Yang Y.Z., Kwok A., **Clee S.M.**, Zwarts K., Marcel M., Newman S., Roomp K., Singaraja R., Zhang L.H., Kastelein J.J.P., Genest J., and Hayden M.R. Truncation mutations in human ABCA1 suppress normal upregulation of wild-type ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. *Oral presentation*, 74th Scientific Sessions of the American Heart Association, Anaheim CA Nov. 11-14, 2001. *Circulation* 2001 104 (17):1397.
 22. **Singaraja R.S.**, Fievet C., Castro G., James E., **Clee S.**, Hennuyer N., Choy J., Bissada N., McManus B., Staels B., and Hayden M.R. Increased HDL and changes in lipoprotein composition are associated with increased efflux and atheroprotection in an ABCA1 BAC transgenic mouse model. *Oral presentation*, 75th Scientific Sessions of the American Heart Association, Chicago IL Nov. 17-20, 2002. *Circulation* 2002 106 (19):219.
 23. **Clee S.M.**, Stoehr J.P., Rabaglia M.E., Schueler K. L., and Attie A.D. Fine-Mapping of a type-II diabetes gene. *Oral presentation*, Keystone Symposium Toward Understanding Islet Biology, Keystone CO, Jan. 21-26, 2003.

24. **Clee S.M.**, Stoehr J.P., Rabaglia M.E., Schueler K. L., and Attie A.D. Fine-mapping and characterization of a type-II diabetes gene. *Oral presentation*, Wisconsin Symposium III, Madison WI, May 20-23, 2003.
25. **Clee S.M.**, Gray-Keller M., Rabaglia M.E., Stapleton D., Raess P.W., and Attie A.D. The BTBR-*ob/ob* model of type II diabetes is characterized by ultrastructural abnormalities consistent with impaired mitochondrial function. *Poster presentation*, Keystone Symposium Diabetes Mellitus: Molecular Mechanisms, Genetics and New Therapies, Keystone CO, Jan. 27-Feb. 2, 2005.
26. **Clee S.M.**, Yandell B., Schueler K.M., Taylor K.D., Goodarzi M.O., Rabaglia M.E., Kabara E.A., Klass D.M., Stapleton D.S., Guo X., Cui J., Stoehr J.P., Lan H., Quinones M.J., Hsueh W.A., Gray-Keller M.P., Boronenkov I., Raines S.M., Young M.B., Raess P.W., Flowers M.T., Rotter J.I., and Attie A.D. Positional cloning of a type II diabetes susceptibility gene: *SorCS1*. *Poster presentation*, Keystone Symposium Diabetes Mellitus and the Control of Cellular Energy Metabolism, Vancouver BC, Jan. 21-26, 2006.
27. **Clee S.M.**, Yandell B., Schueler K.M., Taylor K.D., Goodarzi M.O., Rabaglia M.E., Kabara E.A., Klass D.M., Stapleton D.S., Guo X., Cui J., Stoehr J.P., Lan H., Quinones M.J., Hsueh W.A., Gray-Keller M.P., Boronenkov I., Raines S.M., Young M.B., Raess P.W., Flowers M.T., Rotter J.I., and Attie A.D. Positional cloning of a type II diabetes susceptibility gene: *SorCS1*. *Poster presentation*, Wisconsin Symposium on Human Biology, Madison WI, May 22-25, 2006.
28. **Clee S.M.**, Yandell B., Schueler K.M., Taylor K.D., Goodarzi M.O., Rabaglia M.E., Kabara E.A., Klass D.M., Stapleton D.S., Guo X., Cui J., Stoehr J.P., Lan H., Quinones M.J., Hsueh W.A., Gray-Keller M.P., Boronenkov I., Raines S.M., Young M.B., Raess P.W., Flowers M.T., Rotter J.I., and Attie A.D. Positional cloning of a type II diabetes susceptibility gene: *SorCS1*. *Poster presentation (late breaking)*, American Diabetes Association 66th Scientific Sessions, Washington DC, June 9-13, 2006. *Diabetes* 2006.

(f) *Other*

(g) *Conference Participation (Organizer, Keynote Speaker, etc.)*

10. SERVICE TO THE UNIVERSITY

(a) *Memberships on committees, including offices held and dates*

(b) *Other service, including dates*

11. SERVICE TO THE COMMUNITY

(a) *Memberships on scholarly societies, including offices held and dates*

- Member, Canadian Obesity Network (2006+)
- Member, Canadian Diabetes Association (2007+)

(b) *Memberships on other societies, including offices held and dates*

(c) *Memberships on scholarly committees, including offices held and dates*

(d) *Memberships on other committees, including offices held and dates*

(e) *Editorships (list journal and dates)*

(f) *Reviewer (journal, agency, etc. including dates)*

- *Clinical Genetics* (2001+)
- *Physiological Genomics* (2007+)
- *Genome Biology* (2007+)

(g) *External examiner (indicate universities and dates)*

(h) *Consultant (indicate organization and dates)*

- Xenon Genetics Inc. (Now Xenon Pharmaceuticals, Inc.) 2000-2002

(i) *Other service to the community*

12. **AWARDS AND DISTINCTIONS**

(a) *Awards for Teaching (indicate name of award, awarding organizations, date)*

(b) *Awards for Scholarship (indicate name of award, awarding organizations, date)*

- American Heart Association Postdoctoral Fellowship 2005-2006
- Keystone Symposia Scholarship, 2005
- American Heart Association Postdoctoral Fellowship 2003-2005
- Keystone NIH Scholarship, 2003

(c) *Awards for Service (indicate name of award, awarding organizations, date)*

(d) *Other Awards*

13. **OTHER RELEVANT INFORMATION (Maximum One Page)**

THE UNIVERSITY OF BRITISH COLUMBIA
Publications Record

SURNAME: CLEE

FIRST NAME: Susanne

Initials:

MIDDLE NAME(S): M

Date:

1. REFEREED PUBLICATIONS**(a) Journals**

1. Kelly N., **Clee S.**, and Nakielna, B. Bioactive Tumor Necrosis Factor in the Sputum of Cystic Fibrosis Patients. *Clinical and Diagnostic Lab. Immunol.* 1995 **2**:499-502.
2. Zhang H., Henderson H., Gagne S. E., **Clee S. M.**, Miao L., Liu G., and Hayden M. R. Common Sequence Variants of Lipoprotein Lipase: Standardized Studies of In Vitro Expression and Catalytic Function. *Bioch. Biophys. Acta* 1996 **1302**:159-166.
3. Pimstone S. N., **Clee S. M.**, Gagne S. E., Miao L., Zhang H., Stein E. A., and Hayden M. R. A Frequently Occurring Mutation in the Lipoprotein Lipase Gene (Asn291Ser) Results in Altered Postprandial Chylomicron Triglyceride and Retinyl Palmitate Response in Normolipidemic Carriers. *J. Lipid Res.* 1996 **37**:1675-1684.
4. Pimstone S. N., Defesche J. C., **Clee S. M.**, Bakker H. D., Hayden M. R., and Kastelein J. J. P. Differences in the Phenotype Between Children With Familial Defective Apolipoprotein B-100 and Familial Hypercholesterolemia. *Arterioscler. Thromb. Vasc. Biol.* 1997 **17**:826-833.
5. **Clee S. M.**, Zhang H., Bissada N., Miao L., Ehrenborg E., Benlian P., Shen G. X., Angel A., LeBoeuf R. C., and Hayden M. R. Relationship Between Lipoprotein Lipase and High Density Lipoprotein Cholesterol in Mice: Modulation by Cholesteryl Ester Transfer Protein and Dietary Status. *J. Lipid Res.* 1997 **38**(10):2079-2089.
6. Ginzinger D. G., Wilson J. E., Redenbach D., Lewis M. E. S., **Clee S. M.**, Excoffon K. J. D. A., Rogers Q. R., Hayden M. R., and McManus B. R. Diet-Induced Atherosclerosis in the Domestic Cat. *Lab. Invest.* 1997 **77**(5):409-419.
7. Ehrenborg E., **Clee S. M.**, Pimstone S. N., Reymer P. W. A., Benlian P., Hoogendijk C. F., Davis H. J., Bissada N., Miao L., Gagne S. E., Greenberg L. J., Henry R., Henderson H., Ordovas J. M., Schaefer E. J., Kastelein J. J. P., Kotze M. J., and Hayden M. R. Ethnic Variation and In Vivo Effects of the -93t→g Promoter Variant in the Lipoprotein Lipase Gene. *Arterioscler. Thromb. Vasc. Biol.* 1997 **17**:2672-2678.
8. Ginzinger D. G., **Clee S. M.**, Dallongeville J., Lewis M. E. S., Henderson H. E., Bauje E., Rogers Q. R., Jansen D., Eckel R., Dyer R., Innis S., Jones B., Fruchart J.-C., and Hayden M. R. Lipid and Lipoprotein Analysis of Cats with Lipoprotein Lipase Deficiency. *Eur. J. Clin. Invest.* 1999 **29**:17-26.
9. Brooks-Wilson A., Marcil M., **Clee S. M.**, Zhang L.-H., Roomp K., van Dam M., Yu L., Brewer C., Collins J. A., Molhuizen H.O.F., Loubser O., Ouelette B.F.F., Fichter K., Ashbourne-Excoffon K.J.D., Sensen C.W., Scherer S., Mott S., Denis M., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J.P., Genest J. Jr., and Hayden M.R. Mutations in the ATP binding cassette (ABC1) transporter gene in Tangier disease and Familial HDL Deficiency (FHA). *Nat. Genet.* 1999 **22**:336-345.
10. Marcil M., Brooks-Wilson A., **Clee S. M.**, Roomp K., Zhang L.-H., Brewer C., Collins J. A., Loubser O., Ouelette B.F.F., Fichter K., Yu L., Mott S., Denis M., Martindale D., Koop B., Pimstone S., Kastelein J.J.P., Genest J. Jr., and Hayden M.R. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. *Lancet* 1999 **354**(9187):1341-6.
11. **Clee S. M.**, Bissada N., Miao F., Miao L., Marais A. D., Henderson H. E., Steures P., McManus J., McManus B., LeBoeuf R. C., Kastelein J. J. P., and Hayden M. R. Plasma and vessel wall lipoprotein lipase have different roles in atherosclerosis. *J. Lipid Res.* 2000 **41**:521-531.
12. Kastelein J. J. P., Jukema J. W., Zwinderman A. H., **Clee S. M.**, van Boven A. J., Jansen H., Rabelink T. J., Peters R. J. G., Lie K. I., Liu G., Bruschke A. V. G., and Hayden M. R. Also on behalf of the REGRESS Study Group. Lipoprotein lipase activity is associated with severity of angina pectoris. *Circulation* 2000 **102**(14):1629-1633.
13. **Clee S. M.**, Kastelein J.J.P., van Dam M., Marcil M., Roomp K., Zwarts K.Y., Collins J.A., Roelants R., Tamasawa N., Stulc T., Suda T., Ceska R., Boucher B., Rondeau C., DeSouich C., Brooks-Wilson A., Molhuizen H.O.F., Frohlich J., Genest J. Jr., and Hayden M.R. HDL levels and coronary artery disease in heterozygotes for ABCA1 mutations are predicted by levels of cholesterol efflux and are influenced by age. *J. Clin. Invest.* 2000 **106**:1263-1270. *Commentary: Tall and Wang, J. Clin. Invest.* 2000 **106**:1205-1207.

14. **Clee S. M.**, Zwinderman A.H., Engert J.C., Zwarts K.Y., Molhuizen H.O.F, Roomp K., Jukema J.W., van Wijland M., van Dam M., Hudson T.J., Brooks-Wilson A., Genest, J. Jr., Kastelein J.J.P., and Hayden M.R. Common genetic variation in *ABCA1* is associated with altered lipoprotein levels and a modified risk for coronary artery disease. *Circulation* 2001 **103**:1198-1205 and r13-r20 (rapid track, online).
15. Backus R. C., Ginzing D. G., Ashbourne-Excoffon K. J. D. A., **Clee S. M.**, Hayden M. R., Eckel R. H., Hickman M. A., and Rogers Q. R. Maternal expression of functional lipoprotein lipase and effects on body fat mass and condition scores of mature cats with lipoprotein lipase deficiency. *Am. J. Vet. Res.* 2001 **62**(2):264-269.
16. Singaraja R., Bocher V., James E.R., Clee S.M., Zhang L.H., Leavitt B.R., Tan B., Brooks-Wilson A., Kwok A., Bissada N., Yang Y., Liu G., Trafuri S.R., Fievet C., Wellington C.L., Staels B., and Hayden M.R. Human *ABCA1* BAC transgenic mice show increased HDL-C and apoA1 dependent efflux stimulated by an internal promoter containing liver X response elements in intron 1. *J. Biol. Chem.* 2001 276(36):33969-33979.
17. McGladdery S.H., Pimstone S.N., **Clee S.M.**, Bowden J.F., Hayden M.R., and Frohlich J.J. Common mutation in the lipoprotein lipase gene: effects on HDL-cholesterol levels in a Chinese Canadian population *Atheroscler.* 2001 **156**(2):401-407.
18. **Clee S.M.**, Loubser O., Collins J. A., Kastelein J. J. P., and Hayden M. R. The LPL S447X cSNP is associated with decreased blood pressure, plasma triglycerides and risk of coronary artery disease. *Clin. Genet.* 2001 **60**(4):293-300.
19. van Dam M., de Groot E., **Clee S.M.**, Hovingh G.K., Roelants R., Brooks-Wilson A., Zwinderman A.H., Smit A.J., Smelt A.H.M., Groen A.K., Hayden M.R., and Kastelein J.J.P. Association between increased arterial wall thickness and impairment in *ABCA1* driven cholesterol efflux: an observational study. *Lancet* 2002 **359**(9300):37-42.
20. Zwarts K.Y., **Clee, S.M.**, Zwinderman A.H., Engert J., Jukema J.W., Roomp K., Hudson T.J., Brooks-Wilson A., Kastelein J.J.P., and Hayden M.R. *ABCA1* regulatory variants influence coronary artery disease independent of effects on plasma lipid levels. *Clin. Genet.* 2002 **61**(2):115-125.
21. Singaraja R.R., Fievet C., Castro G., James E.R., **Clee S.M.**, Bissada N., Choy J.C., Fruchart J.-C., McManus B.M., Staels B., and Hayden M.R. Increased expression of *ABCA1* protects against atherosclerosis. *J. Clin. Invest.* 2002 **110**:35-42.
22. Wellington C.L., Yang Y.-Z., Zhou S., **Clee S.M.**, Tan B., Hirano K., Zwarts K., Kwok A., Gelfer A., Marcil M., Newman S., Roomp K., Singaraja R., Collins J., Zhang L.H., Groen A.K., Hovingh K., Brownlie A., Tafuri S., Genest J. Jr., Kastelein J.J.P., and Hayden M.R. Truncation mutations in *ABCA1* suppress normal upregulation of full-length *ABCA1* by 9-cis-retinoic acid and 22-R-hydroxycholesterol. *J. Lipid Res.* 2002 **43**(11):1939-1949.
23. Stoehr J.P., Byers J.E., **Clee S.M.**, Lan H., Boronkov I., Schueler K.M., Yandell B.S., and Attie A.D. Detection of major quantitative trait loci controlling body weight variation in *ob/ob* mice. *Diabetes* 2004 **53**:245-249.
24. **Clee S.M.**, Yandell B., Schueler K.M., Rabaglia M.E., Richards O.R., Raines S.M., Kabara E.A., Klass D.M., Mui, E.T.-K., Stapleton D.S., Gray-Keller M.P., Young M.B., Stoehr J.P., Lan H., Boronkov I., Raess P.W., Flowers M.T., and Attie A.D. Positional cloning of *SorCS1*, a type 2 diabetes quantitative trait locus. *Nat. Genet.* 2006 **38**:688-693.
25. **Clee S.M.** and Attie A.D. The genetic landscape of type 2 diabetes in mice. *Endocrine Reviews* 2007 **28**:48-83.
26. Goodarzi M.O., Lehman D.M., Taylor K.D., Guo X., Cui J., Quinones M.J., **Clee S.M.**, Yandell B.S., Blangero J., Hsueh W.A., Yang H., Attie A.D., Stern M.P., and Rotter J.I. *SORCS1*: A novel human type 2 diabetes susceptibility gene suggested by the mouse. *Diabetes* 2007 **56**:1922-1929.

(b) *Conference Proceedings*

(c) *Abstracts*

1. Pimstone S. N., Gagne E., **Clee S. M.**, Stein E. A., and Hayden M. R. Post Prandial Retinyl Palmitate Response Supports Evidence for a Functional Effect of the Asn291Ser Mutation in the Lipoprotein Lipase Gene. 68th Scientific Sessions of the American Heart Association. *Circulation* 1995 92 (8, Suppl.):I493.
2. **Clee S. M.**, Zhang H., Benlian P., Miao L., Bissada N., Shen G. X., Angel A., LeBoeuf R. C., and Hayden M. R. Lipoprotein Lipase Increases HDL Cholesterol Levels in Mice Expressing Cholesterol Ester Transfer Protein. 69th Scientific Sessions of the American Heart Association. *Circulation* 1996 **94** (8, Suppl.): I399.

3. **Clee, S. M.**, Bissada N., Miao F., Miao L., Steures P., Marais A. D., McManus J., McManus B., Henderson H. E., and Hayden M. R. Atherogenicity of Lipoprotein Lipase is Related to Its Site of Expression: *In Vivo* Evidence of Vessel Wall versus Plasma Effects. 71st Scientific Sessions of the American Heart Association. *Circulation* 1998 98(17):I-531
4. Kastelein J. J. P., Wittekoek M. E., Loubser O., **Clee S. M.**, Collins J., Moll E., Pimstone S. N., and Hayden M. R. Common Variants of Lipoprotein Lipase (LPL) Strongly Influence Levels of Lipids and Lipoproteins and Coronary Artery Disease (CAD) in Patients with Familial Hypercholesterolemia (FH). 71st Scientific Sessions of the American Heart Association. *Circulation* 1998 98(17):I-739.
5. Brooks-Wilson A., Marcil M., **Clee S. M.**, Zhang L.-H., Roomp K., van Dam M.J., Yu L., Brewer C., Collins J.A., Molhuizen H.O.F., Ouellette B.F.F., Sensen C.W., Martindale D., Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J.P., Genest J. Jr., Hayden M.R. Mutations in transportin (ABCA1) in Tangier disease and familial HDL deficiency. American Society of Human Genetics. *American Journal of Human Genetics* 1999 65(4 suppl):A34.
6. **Clee S. M.**, Loubser O., Collins J., Kastelein J. J. P, and Hayden M. R. The lipoprotein lipase S447X variant is associated with decreased systolic and diastolic blood pressure. 72nd Scientific Sessions of the American Heart Association. *Circulation* 1999 100(18):1822.
7. **Clee S.M.**, Zwarts K.Y., Roomp K., Collins J.A., Marcil M., van Dam M., Brooks-Wilson A., Genest J. Jr., Kastelein J.J.P., and Hayden M.R. HDL levels in ABCA1 heterozygotes are predicted by cholesterol efflux levels and are influenced by age. American Society of Human Genetics 50th annual meeting. *American Journal of Human Genetics* 2000 67(4 Suppl 2):350.
8. Molhuizen H.O.F., **Clee S.M.**, Zwinderman A.H., Engert J., Zwarts K.Y., Brooks-Wilson A., Hudson T., Jukema J.W., Kastelein J.J.P., and Hayden M.R. cSNP analysis of the ABCA1 gene: the R219K variant is associated with a blunted age-modulated increase in HDL cholesterol and decreased coronary artery disease (CAD). American Society of Human Genetics 50th annual meeting. *American Journal of Human Genetics* 2000 67(4 Suppl 2):233.
9. **Clee S.M.**, Zwarts K.Y., Roomp K., Collins J.A., van Dam M., Marcil M., Brooks-Wilson A., Genest J. Jr., Kastelein J.J.P., and Hayden M.R. The age modulated phenotype in heterozygotes for mutations in ABC1 includes significantly decreased HDL, increased triglycerides and an increased frequency of coronary artery disease (CAD). 73rd Scientific Sessions of the American Heart Association. *Circulation* 2000 102 (18):II-31.
10. **Clee S.M.**, Molhuizen H.O.F., Zwinderman A.H., Engert J.C., Roomp K., Zwarts K.Y., Jukema J.W., Hudson T.J., Brooks-Wilson A., Kastelein J.J.P., and Hayden M.R. cSNPs within the ABC1 gene influence HDL cholesterol levels and risk of coronary artery disease (CAD). 73rd Scientific Sessions of the American Heart Association. *Circulation* 2000 102 (18):II-278.
11. **Clee S.M.**, Zwarts K.Y., Zwinderman A.H., Engert J.C., Roomp K., Jukema J.W., Hudson T.J., Brooks-Wilson A., Kastelein J.J.P., and Hayden M.R. ABCA1 regulatory variants influence CAD independent of effects on plasma lipid levels. 74th Scientific Sessions of the American Heart Association. *Circulation* 2001 104 (17):2131.
12. Wellington C.L., Yang Y.Z., Kwok A., **Clee S.M.**, Zwarts K., Marcel M., Newman S., Roomp K., Singaraja R., Zhang L.H., Kastelein J.J.P., Genest J., and Hayden M.R. Truncation mutations in human ABCA1 suppress normal upregulation of wild-type ABCA1 by 9-cis-retinoic acid and 22-R-hydroxycholesterol. 74th Scientific Sessions of the American Heart Association. *Circulation* 2001 104 (17):1397.
13. Singaraja R.S., Fievet C., Castro G., James E., **Clee S.**, Hennuyer N., Choy J., Bissada N., McManus B., Staels B., and Hayden M.R. Increased HDL and changes in lipoprotein composition are associated with increased efflux and atheroprotection in an ABCA1 BAC transgenic mouse model. 75th Scientific Sessions of the American Heart Association. *Circulation* 2002 106 (19):1105.
14. **Clee S.M.**, Yandell B., Schueler K.M., Taylor K.D., Goodarzi M.O., Rabaglia M.E., Kabara E.A., Klass D.M., Stapleton D.S., Guo X., Cui J., Stoehr J.P., Lan H., Quinones M.J., Hsueh W.A., Gray-Keller M.P., Boronenkov I., Raines S.M., Young M.B., Raess P.W., Flowers M.T., Rotter J.I., and Attie A.D. Positional cloning of a type II diabetes susceptibility gene: *SorCS1*. American Diabetes Association 66th Scientific Sessions. *Diabetes* 2006.

(d) Other

2. NON-REFEREED PUBLICATIONS

(a) *Journals*

Editorial Review only

1. Hayden M. R., **Clee S. M.**, Brooks-Wilson A., Genest Jr. J., Attie A. and Kastelein J.J.P. Cholesterol Efflux Regulatory Protein (CERP), Tangier Disease and Familial HDL Deficiency. *Curr. Opin. Lipidol.* 2000 **11**:117-122.
2. **Clee S.M.** Getting at the heart of coronary disease. *Clin. Genet.* 2004 **65**:347-9.
3. **Clee S.M.** Genomics goes to the dogs. *Clin. Genet.* 2004 **65**:349-351.
4. **Clee S.M.** Expressing the nature of quantitative traits. *Clin. Genet.* 2005 **68**:1-5.
5. **Clee S.M.** Sweet successes in diabetes genetics. *Clin. Genet.* 2007 **72**:83-86.

(b) *Conference Proceedings*

1. **Clee S.M.**, Nadler S.N., and Attie A.D. Genetic and genomic studies of the BTBR *ob/ob* mouse model of type 2 diabetes. *Am. J. Ther.* 2005 **12**:491-8.

(c) *Other*

3. **BOOKS**

(a) *Authored*

(b) *Edited*

(c) *Chapters*

4. **PATENTS**

1. **Clee S.M.**, Brooks-Wilson A.R., Hayden M.R., and Pimstone S.N. Compositions and methods for modulating HDL cholesterol and triglyceride levels. Published Mar. 8, 2001. Publication # WO 01/15676 A2.
2. Hayden M.R., Zwarts K.Y., and **Clee S.M.** Diagnostic methods for cardiovascular disease, low HDL-cholesterol levels and high triglyceride levels. Published Dec. 5, 2002. Publication # WO 02/097123 A2.

5. **SPECIAL COPYRIGHTS**

6. **ARTISTIC WORKS, PERFORMANCES, DESIGNS**

7. **OTHER WORKS**

8. **WORK SUBMITTED** (including publisher and date of submission)

9. **WORK IN PROGRESS** (including degree of completion)

1. **Clee S.M.**, Rabaglia M.E., Schueler K.M., Stapleton D.S., Yandell B.S., Ranheim T., Gray-Keller M.P., Raess P.W., and Attie A.D. *Obese BTBR mice are a model of altered β -cell dynamics leading to severe type 2 diabetes.* (formatting for resubmission, expected submission Jan 08)



Analysis Tools

Quick
SearchesPredefined
QueriesQuery
BuilderDatabank
Info

Entry View

Text Entry | DnaDB_Entry

<< Back to Results Set as Primary Search

Entry 2 of 21

Go To: General Description References Features Sequence

General Information About The Entry

Entry Name **GENBANK:AF195056**
 Identifier **AF195056**
 Accession # AF195056
 Molecule Type mRNA
 Sequence Length 3780
 Entry Division ROD (Rodent)
 Sequence Version AF195056.1
 GI 7715915
 Creation Date 08-MAY-2000

Description


Description Mus musculus SorCSb splice variant of the VPS10 domain receptor SorCS (SorCS1a) mRNA
 Organism Mus musculus
 Organism Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria
 Classification Rodentia; Sciurognathi; Muroidea; Muridae; Murinae; Mus.

References

1. Hermey, G. Schaller, H.C.; **Alternative splicing of murine SorCS leads to two forms completely in their cytoplasmic tails** Biochim. Biophys. Acta 1491:350-354 (2000)
 PubMed [10760602](#)
 Position 1-3780
2. Hermey, G.; **Direct Submission** Submitted (14-OCT-1999) Zentrum f. Molekulare Neuro Entwicklungsneurobiologie, Martinistr. 52, Hamburg 20246, Germany
 Position 1-3780

Features

Key	Location	Qualifier	Value
<u>source</u>	1..3780	organism	Mus musculus
		mol_type	mRNA
		db_xref	taxon:10090
gene	1..3780	gene	SorCS1a
CDS	18..3521	gene	SorCS1a
		codon_start	1



T
O
O
L
S

product SorCSb splice variant of the VPS10 domain receptor SorCS
protein_id [AAF68196.1](#)
db_xref [GI:7715916](#)
translation MGKVGAGDGSSAGLSALLAGAGLLMLLAPGVCSLSLSCP
 PQHPS

Sequence

Characteristics Length:3780

Sequence

>AF195056 Mus musculus SorCSb splice variant of the VPS10 domain
 recep...
151920, 151
Untranslated Region nt 1-17 ←
 ttctctacgctccagagatgggaaaagttggcgctggagacgggtcctcggccgggctga
 gcgcgctccttgaggagcggggcttctgatgctcttagccccggcgctctgcagcagcc
 tctcttgctgccctccgcagcaccctagctcgacccccacgccggacccttaccccaagag
 gctttcctcaccgggacctctgggtcgggctcctgccacgccccgcccctcttcatga
 gaccctgttcgcagtggccccggggaccgtgcgctgtttctggagcgagctgggggca
 gcagggtgtcagtgggcgaccgctgcacgctctggccgtaggagacggagtggaaacggaac
 ccgagaagattgaaccgggagaggggtgcgagtcggagccgcccgggacatgctaaaggatg
 gagggcagcaggggcttgggactggcgacgggacccgggcaaagccaccgcttccgga
 tggaggagctgagactgaccagcaccacatttgctctgacaggagactcagcacacaacc
 aagctatgggtccactgggtctggccacaacagcagcgtgattctcattttgacaaagctct
 atgactataacctggggagtatcaccgagagctcgctttggagggtcaaccgattatggga
 ctacctatgaaaagttgaatgataaagtgggggtgaagacaattttgagctatctctatg
 tgtgtccaaccaacaagtgtgaagattatgttactcacagaccggagattgagagcagtt

Go To: [General](#) [Description](#) [References](#) [Features](#) [Sequence](#)

[Quick
Searches](#)

[Predefined
Queries](#)

[Query
Builder](#)

[Analysis
Tools](#)

[Custom
View](#)

[Query
History](#)

[Projects](#)

[Databank
Info](#)

>AF195056 Mus musculus SorCSb splice variant of the VPS10 domain recep...

ttctctacgctccagagatgggaaaagtgtggcgctggagacggctcctcgccgggctga
gcgcgctccttgcaggagcggggcttctgatgctcttagccccggcgtctgcageagcc
tctcttgcctccgcagcaccctagctcgacccacgccggacccttaccccaagag
gcttctcaccgggacctctgggtcgggtcctgccacgccccgccccttctcatga
gaccctgttcgcagtggccccggggaccgtgcgctgttctggagcgagctgggggca
gcagggtgtcagtgccgaccgctgcacgctctggccgtaggagacggagtggaacggaac
ccgagaagattgaacccggagagggtcgagtcggagccgccgggacatgctaaaggatg
gagggcagcaggggcttgggactggcgacgggacccgggcaaagccacccgcttccgga
tggaggagctgagactgaccagcaccacatttgccttgacaggagactcagcacacaacc
aagctatggtccactggtctggccacaacagcagcgtgattctcatttgcacaagctct
atgactataacctggggagtatcaccgagagctcgcttggaggtcaaccgattatggga
ctacctatgaaaagtgaatgataaagtggggtgaagacaattttagctatctctatg
tgtgtccaaccaacaagtgaagattatgttactcacagaccggagattgagagcagtt
tgttgatcagctcagatgaagggcaacctatcaaaagtaccggctcaactttaccttc
agagtttgccttccatccgaagcaagaagactggatcctggcatacagtcagacaaa
agttatacagctctgctgagtttggccgaagatggcagcttatccaggaatcagtggtac
caaataaggttctactggtctgtgatgggtcgagcaaagaaccagacctgtgcatctcg
aggccaggactgtggatggtcactcaatatacctaactgtcggatgcaaaactgcactg
aagccaacagaaataagccttcccaggttacatcgacccggactcttgattgttcagg
acgattatgtgtttgtcagctgacatcaggaggaagaccacattactatgtgtcctacc
gaagaagcccgttgcacaaaatgaagcttccgaaatacgttggccaaggacatgcacg
tcattagcacagacgagaaccaagtgttgcagccgttcaagaatggaaccagaacgaca
cctacaacctctacatctcagacacacgaggagtctacttcacactggccttgagaatg
tgcggagcagcagaggccctgaaggcaacgtcatgattgacctttatgaggtagcaggga
taaagggaatgttcttggttaacaagaagattgacaaccaagtgaagacttcatcactt
acaacaaaggcagagactggcggttctgcaggtccagatgcagatctaaggggggacc
ctgtgcactgttctgcctactgttcgtacaccttcacctgaaggtttctgagaatc
cctacacatccgggatcattgccagcagagacacagccccagttattatagttgcatcag
gtaacataggctctgagttgtcagacagtgcacatcagcatgttgtatcttcagatgcag
ggaacacttggaggcagatgttgaagaagagcacagcatttgtaccttgaccaaggtg
gagtccttgttgcataaacaacacatctctcccaattcgacaccttgggtgagtttg
atgaaggagatcttggagcaatacagctttacatccattccactcttgtggtggag
tcttgggggagcctggagaagagacactaatcatgacagtggttggacacttcagtcac
gtccgaatggcagctggtcaaagtggactacaagtccattttagatagacgctgtgctg
aagaagactacagacctggcagttgcatagtcagggggaagcatgcatcatgggagcca
agaggatatacaagaagagaaagtctgagcgcaagtgtatgcaaaagtatgcgggagcaa
tggagcttgagccttgtgttgcacagaggcagacttgcagtgactatggctatgaga
gacatagtaatggacaatgcctgccagcatttgggtcaacctcctcactgtcaaaag
actgcagcttgggacagagttacctcaacagcgtgggtataggaaggtggtctccaata
attgtactgatggagtgcagagcagtataccgccaaccacagaagtgtccagggaagg
cccctcgtgggtcgcggttgcactgcagatgggaaactgacagcagagcagggccaca
atgtcactctcatggtgcagctggaagagggtgatgtgcagcggacactcatccaagtgg
acttcggagatggcattgcagtatcgtatgcaacctcagctctatggaagacggtatca
agcacgtatatcagaatgtgggcatttccgagtaccgtgcaggtggacaacagcttgg
ggtctgacagcggcgtcctgtacttacatgtaactgtccctggagcatgtgcacctgt

7 nt
172

ctcttcttttgcacacaagaacaaagaggtcaatgcaactgcagtgctttggccca
gccaaagtgggcactctcacttacgtgtggttggtatgggaacaacacagagccctgatca
ccttggaggggaagcatatcgttcaagttacttctgaaggaaatgaatactatcacagtcc
aagtctctgctgggaacgccatactgcaagacacaaagaccattgcggtatatgaggaat
ttcggtctcttcgcttggccttttctcgaacttggatgactacaacctgacatccggg
agtggaggaggacatcagccgagtcacaaaaagtcctctggtggaaaccacagggattc
ccagccagcatatcctgggtggcgtgttacctggccttaccactgctgcagagctcttg
tttggcctaccaagatggaaccagggaaaacaaaaggctgcctgaggacctggagcaga
tatctgaagtctaatccacaaactcaacaaaacttgggtgcacttcgagctgaagcctg
gcgtccaagtcttctgccacgcagctcacctgacagcagctccactggtggacctcactc
ctaccacagcggatctgccatgctgatgttgcctctctgtggtgtttgtggggctcgtg
tattcgtcatctacaagttttaaaggagagtagctttacctccccctcccccttctg
ctcaacctggtgactcatctctccgattgcaaagaccaagaccgcaactccacctcat
cgccaaagcggggatctgctggggcacagtttgcaatttaaggaaaaacccccaaaggct
acaggagacctgctgatcagaagagaatttcgctcttgcaagtgcatactcttcatga
ccactaaccttgttttgttttcttctgttgttctgtttcttattttgccagg
aagtatttccatagttgctgagaatcaaagcacaaaaaaatccctacctatgtaaatgt
ttgaatggaggacgccagtaaaacaaacaaaacaaacaaacaaaaaaaaaaaaaaaaaaaa

NCBI Nucleotide

PubMed Nucleotide Protein Genome Structure PMC Taxonomy OMIM Books

Search for

Limits Preview/Index History Clipboard Details

Display Show Send to Hide: ☐ sequence ☐ all but gene, CDS and mRNA

Range: from to ☐ Reverse complemented strand Features: ☐ SNP ☒ STS ☒

☐ 1: [NM_052918](#). Reports Homo sapiens sort...[gi:61743972]

[Links](#)

[Comment](#) [Features](#) [Sequence](#)

LOCUS NM_052918 7272 bp mRNA linear PRI 03-SEP-2007

DEFINITION Homo sapiens sortilin-related VPS10 domain containing receptor 1 (SORCS1), transcript variant 1, mRNA.

ACCESSION NM_052918

VERSION NM_052918.3 GI:61743972

KEYWORDS .

SOURCE Homo sapiens (human)

ORGANISM [Homo sapiens](#)
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 7272)

AUTHORS Deloukas,P., Earthrowl,M.E., Grafham,D.V., Rubenfield,M., French,L., Steward,C.A., Sims,S.K., Jones,M.C., Searle,S., Scott,C., Howe,K., Hunt,S.E., Andrews,T.D., Gilbert,J.G., Swarbreck,D., Ashurst,J.L., Taylor,A., Battles,J., Bird,C.P., Ainscough,R., Almeida,J.P., Ashwell,R.I., Ambrose,K.D., Babbage,A.K., Bagguley,C.L., Bailey,J., Banerjee,R., Bates,K., Beasley,H., Bray-Allen,S., Brown,A.J., Brown,J.Y., Burford,D.C., Burrill,W., Burton,J., Cahill,P., Camire,D., Carter,N.P., Chapman,J.C., Clark,S.Y., Clarke,G., Clee,C.M., Clegg,S., Corby,N., Coulson,A., Dhami,P., Dutta,I., Dunn,M., Faulkner,L., Frankish,A., Frankland,J.A., Garner,P., Garnett,J., Gribble,S., Griffiths,C., Grocock,R., Gustafson,E., Hammond,S., Harley,J.L., Hart,E., Heath,P.D., Ho,T.P., Hopkins,B., Horne,J., Howden,P.J., Huckle,E., Hynds,C., Johnson,C., Johnson,D., Kana,A., Kay,M., Kimberley,A.M., Kershaw,J.K., Kokkinaki,M., Laird,G.K., Lawlor,S., Lee,H.M., Leongamornlert,D.A., Laird,G., Lloyd,C., Lloyd,D.M., Loveland,J., Lovell,J., McLaren,S., McLay,K.E., McMurray,A., Mashreghi-Mohammadi,M., Matthews,L., Milne,S., Nickerson,T., Nguyen,M., Overton-Larty,E., Palmer,S.A., Pearce,A.V., Peck,A.I., Pelan,S., Phillimore,B., Porter,K., Rice,C.M., Rogosin,A., Ross,M.T., Sarafidou,T., Sehra,H.K., Shownkeen,R., Skuce,C.D., Smith,M., Standring,L., Sycamore,N., Tester,J., Thorpe,A., Torcasso,W., Tracey,A., Tromans,A., Tsolas,J., Wall,M., Walsh,J., Wang,H., Weinstock,K., West,A.P., Willey,D.L., Whitehead,S.L., Wilming,L., Wray,P.W., Young,L., Chen,Y., Lovering,R.C., Moschonas,N.K., Siebert,R., Fectel,K., Bentley,D., Durbin,R., Hubbard,T., Doucette-Stamm,L., Beck,S., Smith,D.R. and Rogers,J.

TITLE The DNA sequence and comparative analysis of human chromosome 10

JOURNAL Nature 429 (6990), 375-381 (2004)

PUBMED [15164054](#)

REFERENCE 2 (bases 1 to 7272)

EXHIBIT

C

AUTHORS Hermey,G., Keat,S.J., Madsen,P., Jacobsen,C., Petersen,C.M. and Gliemann,J.

TITLE Characterization of sorCS1, an alternatively spliced receptor with completely different cytoplasmic domains that mediate different trafficking in cells

JOURNAL J. Biol. Chem. 278 (9), 7390-7396 (2003)

PUBMED [12482870](#)

REMARK GeneRIF: human sorCS1 has three isoforms, sorCS1a-c, with completely different cytoplasmic tails and differential expression in tissues

REFERENCE 3 (bases 1 to 7272)

AUTHORS Hampe,W., Rezgaoui,M., Hermans-Borgmeyer,I. and Schaller,H.C.

TITLE The genes for the human VPS10 domain-containing receptors are large and contain many small exons

JOURNAL Hum. Genet. 108 (6), 529-536 (2001)

PUBMED [11499680](#)

COMMENT REVIEWED [REFSEQ](#): This record has been curated by NCBI staff. The reference sequence was derived from [AF284756.1](#), [BE019093.1](#), [AY099452.1](#), [AK125464.1](#) and [AL133395.21](#).
On Mar 24, 2005 this sequence version replaced [gi:18379341](#).

Summary: This gene encodes one family member of vacuolar protein sorting 10 (VPS10) domain-containing receptor proteins. The VPS10 domain name comes from the yeast carboxypeptidase Y sorting receptor Vps10 protein. Members of this gene family are large with many exons but the CDS lengths are usually less than 3700 nt. Very large introns typically separate the exons encoding the VPS10 domain; the remaining exons are separated by much smaller-sized introns. These genes are strongly expressed in the central nervous system. Two of the five family members (sortilin and sortilin-related receptor) are synthesized as preproproteins; it is not yet known if this encoded protein is also a preproprotein. Alternatively spliced transcript variants encoding different isoforms have been identified.

Transcript Variant: This variant (1) represents the longer transcript, but encodes the shorter isoform (a).
COMPLETENESS: complete on the 3' end.

PRIMARY	REFSEQ_SPAN	PRIMARY_IDENTIFIER	PRIMARY_SPAN	COMP
	1-477	AF284756.1	1-477	
	478-482	BE019093.1	74-78	
	483-698	AF284756.1	483-698	
	699-1912	AY099452.1	699-1912	
	1913-1948	AK125464.1	2087-2122	
	1949-3379	AY099452.1	1949-3379	
	3380-3729	AF284756.1	3380-3729	
	3730-7272	AL133395.21	51551-55093	c

FEATURES

source Location/Qualifiers

1..7272

/organism="Homo sapiens"

/mol_type="mRNA"

/db_xref="taxon:9606"

/chromosome="10"

/map="10q23-q25"

gene 1..7272

/gene="SORCS1"

/note="sortilin-related VPS10 domain containing receptor 1; synonyms: FLJ41758, FLJ43475, FLJ44957"

/db_xref="GeneID:114815"

/db_xref="HGNC:16697"

exon /db_xref="HPRD:12098"
/db_xref="MIM:606283"
1..566
/gene="SORCS1"
/inference="alignment:Splign"
/number=1

CDS 9..3515
/gene="SORCS1"
/GO_component="integral to membrane; membrane [PMID
12482870]"
/GO_function="neuropeptide receptor activity [PMID
11499680]; protein binding [PMID 12482870] [PMID
12482870]; protein transporter activity"
/GO_process="intracellular protein transport; neuropeptide
signaling pathway [PMID 11499680]"
/note="isoform a is encoded by transcript variant 1"
/codon_start=1
/product="SORCS receptor 1 isoform a"
/protein_id="NP_443150.3"
/db_xref="GI:61743973"
/db_xref="CCDS:CCDS7559.1"
/db_xref="GeneID:114815"
/db_xref="HGNC:16697"
/db_xref="HPRD:12098"
/db_xref="MIM:606283"
/translation="MGKVGAGGGSQARLSALLAGAGLLILCAPGVCGGGSCCPSPHPS
SAPRSASTPRGFHQGRPGRAPATPLPLVVRPLFSVAPGDRALSLERARGTGASMAVA
ARSGRRRRSGADQEKAERGEGASRSPRGVLRDGGQQEPGTRERDPDKATFRMEELRL
TSTTFALTGDSAHNQAMVHWSGHNSSVILILTKLYDYNLGSITESSLWRSTDYGTYYE
KLNDKVGLKTILSYLYVCPTNKRKIMLLTDPEIESSLLISSDEGATYQKYRLNFYIQS
LLFHPKQEDWILAYSQDQKLYSSAEFGRRWQLIQEGVVPNRFYWSVMGSNKEPDLVHL
EARTVDGHSYLTTCRMQNCTEARNRNPFGYIDPDSLIVQDHYVVFVQLTSGGRPHYVY
SYRRNAFAQMKLPKYALPKDMHVISTDENQVFAAVQEWNQNDTYNLYISDTRGVYFTL
ALENVQSSRGPEGNIMIDLYEVAGIKGMFLANKKIDNQVKTFITYNKGRDWRLQAPD
TDLRGDPVHCLLPYCSLHLHLKVSENPYTSGIISKDTAPSIIVASGNIGSELSDTDI
SMFVSSDAGNTWRQIFEEHVSPLYLDQGGVLVAMKHTSLPIRHLWLSFDEGRSWSKYS
FTSIPLFVDGVLGEPGEETLIMTVFGHFSHRSEWQLVKVDYKSIFDRRCAEEDYRPWQ
LHSQGEACIMGAKRIYKKRKSERKCMQKGKYAGAMESEPCVCTEADFCDYGYERHSNG
QCLPAFWFNPSSLKDCSLGQSYLNSTGYRKVVSNNCTDGVREQYTAKPQKCPGKAPR
GLRIVTADGKLTAEQGHNVTLMVQLEEGDVQRTLIQVDFGDGIAVSYNLSSMEDGIK
HVVQNVGIFRVTVQVNSLGSDSAVLYLHVTCPLEHVHLSLPFVTTKNKEVNATAVLW
PSQVGTLYVWYGNNTTEPLITLEGSISFRFTSEGMNTITVQVSAGNAILQDTKTIIV
YEEFRSLRLSFSPNLDDYNPDIPWRRDIGRVIKKSLEATGVPGQHILVAVLPGLPT
TAEFLVLPYQDPAGENKRSTDDLEQISELLIHTLNQNSVHFELKPGVRVLVHAHLTA
APLVDLTPTHSGSAMLMLLSVVFVGLAVFVIYKFKRRVALPSPSPSTQPGDSSLRLQ
RARHATPPSTPKRGSAGAQYAI"

exon 567..634
/gene="SORCS1"
/inference="alignment:Splign"
/number=2

exon 635..734
/gene="SORCS1"
/inference="alignment:Splign"
/number=3

exon 735..893
/gene="SORCS1"
/inference="alignment:Splign"
/number=4

exon 894..967
/gene="SORCS1"

	/inference="alignment:Splign"
	/number=5
<u>exon</u>	968..1032
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=6
<u>exon</u>	1033..1151
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=7
<u>exon</u>	1152..1241
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=8
<u>exon</u>	1242..1421
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=9
<u>exon</u>	1422..1568
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=10
<u>exon</u>	1569..1671
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=11
<u>exon</u>	1672..1748
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=12
<u>exon</u>	1749..1840
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=13
<u>exon</u>	1841..1948
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=14
<u>exon</u>	1949..2066
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=15
<u>exon</u>	2067..2197
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=16
<u>exon</u>	2198..2311
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=17
<u>exon</u>	2312..2483
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=18
<u>exon</u>	2484..2670
	/gene="SORCS1"
	/inference="alignment:Splign"
	/number=19
<u>exon</u>	2671..2804
	/gene="SORCS1"

```

                /inference="alignment:Splign"
                /number=20
    exon        2805..2928
                /gene="SORCS1"
                /inference="alignment:Splign"
                /number=21
    exon        2929..3041
                /gene="SORCS1"
                /inference="alignment:Splign"
                /number=22
    exon        3042..3173
                /gene="SORCS1"
                /inference="alignment:Splign"
                /number=23
    exon        3174..3273
                /gene="SORCS1"
                /inference="alignment:Splign"
                /number=24
    exon        3274..3379
                /gene="SORCS1"
                /inference="alignment:Splign"
                /number=25
    exon        3380..7272
                /gene="SORCS1"
                /inference="alignment:Splign"
                /number=27a
    STS        4654..4843
                /gene="SORCS1"
                /standard_name="D10S1395E"
                /db_xref="UniSTS:151392"
    STS        4678..4841
                /gene="SORCS1"
                /standard_name="A008R15"
                /db_xref="UniSTS:40984"
    STS        6402..7232
                /gene="SORCS1"
                /standard_name="SORCS1_5283"
                /db_xref="UniSTS:464557"
    STS        6752..6854
                /gene="SORCS1"
                /standard_name="D10S1331E"
                /db_xref="UniSTS:60809"
    polyA_signal 7008..7013
                /gene="SORCS1"
    polyA_site 7030
                /gene="SORCS1"
                /experiment="experimental evidence, no additional details
                recorded"
    polyA_signal 7247..7252
                /gene="SORCS1"
    polyA_site 7272
                /gene="SORCS1"

```

ORIGIN

1st column

```

1  ctccccgcgat gggaaaagtt ggcgcggcg ggcggctccca agcccggtcg agcgcgctcc
61 tgcgcggcgc ggggctcttg atcctctgcg ccccgggcgt ctgcggcggc ggctcctgct
121 gcccctcgcc gcacccacgc tccgctccac gctcggcctc gaccgctagg ggcttttccc
181 accagggggc gccaggcagg gctcctgcca cgccctgccc cctcgtagtg cgtccctgtg
241 tctcagtggc ccccggggac cgagcgctat ccctggagcg ggctcggggc actggggcat
301 ccatggcggt tgctgcacgc tccggccgga ggagacggag cggagcggat caggagaagg
361 cagaacgggg agagggcgcg agtcggagcc cccggggagt gctaagagat ggagggcagc

```

untranslated
Region
(8 nt)

163 nt

```

421 aggagcctgg gactcgggag cgggacccgg acaaagccac ccgcttccgg atggaggagc
481 tgagactgac cagcaccacg tttgcgctga cgggagactc agcacacaac caagccatgg
541 tccactgggtc tggccacaac agcagcgtga ttctcatttt gacaaagctc tatgactata
601 acctggggag catcacagag agctcgcttt ggagggtcaac cgattatgga acaacctatg
661 agaagctgaa tgataaagtt ggtttgaaaa ccattttgag ctatctctat gtgtgtccta
721 ccaacaagcg taagataatg ttactcacag acccgagatg tgagagcagt ttattgatca
781 gctcagatga aggggcaact tatcaaaagt accggctgaa cttctacatt caaagcttgc
841 tttttcacc caaacaagaa gactggattc tggcatacag tcaagacca aagttataca
901 gctctgctga atttgggaga agatggcagc ttatccaaga aggggttgta ccaaacaggt
961 tctactgggtc tgtgatgggg tcaaataaag aaccagacct tgtgcatctt gaggccagaa
1021 ctgtggatgg tcattcacat tatctaactt gccgaatgca gaactgtaca gaggccaaca
1081 ggaatcagcc ttttccaggc tacattgacc cagactcttt gattgttcag gatcattatg
1141 tgtttgttca gctgacatca ggaggcggc cacattacta cgtgtcctac cgaaggaatg
1201 catttgccca aatgaagctt ccgaaatatg ctttgcccaa ggacatgcat gttatcagca
1261 ccgatgagaa tcaggtgttc gcagcgggtc aagaatggaa ccagaatgac acgtacaacc
1321 tctacatctc agacacacgt ggtgtctact tcaccctggc cttggagaat gtccagagca
1381 gcagaggccc tgagggcaac atcatgatcg acctctatga ggtagcaggg ataaagggaa
1441 tgttcttggc taacaagaag attgacaacc aagtgaagac tttcatcaca tataacaaag
1501 gcagagactg gcgtttgctg caggcgccgg acacggatct aaggggggac cccgtgact
1561 gcttgctgcc ctattgctca ctacaccttc acctgaaggt ctctgagaat ccctacacat
1621 cagggatcat tgccagcaaa gacacagctc aagcatcat agtggcatca ggtaatatag
1681 gttctgaatt gtcagacact gacatcagca tgtttgtctc ttcagatgca gggaacacct
1741 ggagacagat ctttgaagaa gagcacagtg tttgtacct ggatcaaggt ggagcctgg
1801 ttgctatgaa acacacatct ctcccaattc gacatctttg gttgagtttt gatgaaggga
1861 gatcttggag caaatacagt ttcacatcta ttccactttt tgtggatggg gttctgggtg
1921 agcctggaga agagactctc atcatgacag tgtttggaca cttcagccac cgctctgaat
1981 ggcagctggc caaagtagat tacaagtcca tttttgatag acggtgtgcc gaagaggact
2041 acagaccttg gcagctgcac agccaggggg aagcatgtat catgggagca aaaaggatat
2101 ataagaagcg aaaatcagag cgggaagtgt tgcaaggaaa atatgcagga gctatggaat
2161 ctgaaccctg tgtctgcaat gaggctgatt ttgattgcga ctatggttat gagcgacaca
2221 gcaatggcca gtgcctgccg gcattttggt tcaatccatc ctctctgtca aaggattgca
2281 gcttgggaca gagttacctc aatagtactg ggtacaggaa ggtgggtttcc aataattgca
2341 ctgatggcgt aagggaacag tacactgcca aaccgcagaa gtgccagggg aaagccccgc
2401 gggggctgcg gatagtcacg gctgatggaa agctgacagc ggaacaagga cacaacgtca
2461 ctctcatggt gcaattagaa gagggtgatg ttcagcggac actcatcaa gtggactttg
2521 gcgatggtat cgcggtgtct tacgtcaatc tcagctccat ggaagatggg atcaaacacg
2581 tctatcagaa cgtgggcatt ttccgtgtga ccgtgcaggt ggacaacagt ctgggttctg
2641 acagcgcgt cctgtactta catgtaactt gtcccttggg gcacgtgcac ctgtctcttc
2701 cctttgtcac cacaagaac aaagaggtca atgcgacggc agtgctgtgg cccagcttaag
2761 tgggcaccct cacttacgtg tgggtgtacg gaaacaacac ggagcctttg atcaccttg
2821 agggaagcat atccttcaga tttacttcag aaggaatgaa taccatcaca gtgcaggtct
2881 cagctgggaa tgccatccta caagacacaa agaccatcgc agtatatgag gaattccggt
2941 ctcttcgctt gtccctttct ccaaacctgg atgactacaa cccggacatc cctgagtgga
3001 ggagggacat cggctcgagtc atcaaaaaat ccctgggtgga agccacaggg gttccaggcc
3061 agcacatcct ggtggcgggtg ctccctggct taccaccac tgctgaactc tttgtcctac
3121 cctatcagga tccagctgga gaaaacaaaa ggtcaactga tgacctggag cagatatcag
3181 aattgctgat ccacacgctc aacccaaact cagtacactt cgagctgaag ccaggagtcc
3241 gagtccttgt ccatgctgct cacttaacag cggccccctt ggtggacctc actccaacce
3301 acagtggatc tgccatgctg atgctgctct cagtgggtgt tgtggggctg gcagtgttcg
3361 tcacttaciaa gtttaaaagg agagtagctt taccctcccc tccctccctt tctactcaac
3421 ctggtgactc atctctccga ttgcaaagag caagacacgc cactccgctt tcaacgcaa
3481 agcggggatc tgctggggca cagtatgcaa ttttaaggaa acccccaaag gctacaggcg
3541 acctgctgat caggaaagaa tttcgctctt gtcaagtaca tcactcttca tgaccactaa
3601 ctttgtgttt tttttctttt ctttgtgttt ctgtttccta ttttgccagg aagtatttcc
3661 atagtgtctg agaatcaaag cacaaaagaa atccctacct atgtaaatgt ttgaattggag
3721 gacgccagta aaaaaacaaa aacaaaaaca aaacaaaaca taaaatataa acaatcaaaa
3781 tccaaacaaa caaacaacaa ctactgcat cgggactttt taattcttca gacacagaca
3841 acaagggttt ttagctttta gcctgtgcat gtggacaata ctctgagaac atgtctggag
3901 gggcagtgta cagggtgctc attttaatgg aaaacactcc cctctccctc tttctcttc
3961 tctctctttt ttctgatcgg tcgtgtttgt agaaaattca taacatatat aggccaaagga

```

4021 aatctgcatg tattttttgga aatattcttgg gctctagatt tatcagctat ttttagcatta
4081 aaggctgatg ggtggattag ctaccccgag ccttttcata agacacaaag acgtgcacag
4141 gagtttgaaa cctgagctg tttctctgtt ccactttcca tactgtcatt tcccttctaa
4201 gtttagctttg gtagctctgt tggtcagcag tggccacaag gctgctttct gcactctctg
4261 tggccacagg aacaaagatg cgagttgaag atccctttgt gccggtagaa taaggaagga
4321 agggaggcag ggaggcaaag catgtcagaa acggacctg gtttctctgt cacctcttct
4381 caccatgatt gcctccctt gcagctttcc ctactcctgc cccaactgca gtaggaaatg
4441 gaatcccat agttacccat tgtcctgtct tcacatttgt ttgtcatcca tgtgtgacca
4501 tgatctgttg atatctttga atctcttccc tccaaacccc aagtaagttg tccttcaact
4561 gttctcagtt tttcttccca aacatattgc tagattctgg acattaaccc tgacgtttcc
4621 taaatactgg cctggcctgt gccgcccctg cccccactac tcacaagttt ctgagccctt
4681 tgtcagtttt gtacattccc aagcatgcca gcttctgtgc ccatggacct tgctgcatcc
4741 tgcacagcag ggttcagttt catgtatctt tgtcttttcc tctagaacct gcctttttca
4801 aatatccctg ctttttccca cctggaaaca tatactgtat gcgaaagagt tgatatatgc
4861 aaagtaattc aaacctggcc atgtactttg gaaaagaaag catagagatg aattgtggtg
4921 ttctcacacc ttaacgaaaa tctcgtgcca tctgattcca gaagattctt gtgagaaatg
4981 ttttgaatgt gtgacaattt cgcagggcaa tttcctcctg tgacggttgc tgttacctgg
5041 tatttccact ctcacagtag aatagaaatg tttgtgaaat aaaactgatt ttaactggaa
5101 ggagaaacag gttaatggac tttgtgttta agagtgtcaa acagtctgag agaataaatg
5161 ggggtcttgt cttacattag ggtgagagtt tgattattta ggatgatccc agtgatttca
5221 tgtgtgctgt ctgacctctg agtatcatag tatcattaaa gtaaagattt aagtctgtat
5281 aaaggaggag agttactgat tggcaaaaaa gattggcaca aagcatgaag aaaccccat
5341 tttcccaggg taatcatgaa agaaggctca gagaaagagg gaaacaaaag cctgttcagc
5401 agaggcccct ttagtattat ggactgggca aagccacta taaactatag gagaaagaag
5461 ttctgataaa cctcttagta tgcctagcct cttcttttgc tatgtcccta agccaacagg
5521 gtataacaca ggccctggtg ataatgaggg tgtcctaaag atcctgatgt ccatgacttc
5581 atgtagttca ggcacagaaa gaatagcaaa gctgctgtca gaagtttgtc aggcagagat
5641 gtttatgggt gaggataccc catatgaatc tgggaaatgg gctaggcctg aggcagtcac
5701 ctattttagt aactcaattg atccccaacc tgccaggctt cctatctcat aggaaacatc
5761 ctcattgatc ctcttcagtt ggagtctccc aaatttaatg tggagacaa agtggttgaa
5821 aatcaaaaga ggctcactca aaccagcaca gggagtcctc agagttgcag ttcaattcat
5881 ttttaattaga aaagtatgaa agaggtataa cactcttatt ctagcacagt gccttgccca
5941 gagtagtagt atgaaaacta tttgttgaag aaataaatga atggaaagac ataggggaaga
6001 atgggctgta aatcctaatt aaaaatagag gtcgacatga gatacctggc attttgggaa
6061 gtgaccaaag atggccagct agagattcag catctccagg atcctcatgt gcctctctc
6121 aaagctccct cccatctgta ggagattagt gaggcaaggt gctgctcaga gaggaggacc
6181 tcattgttct taggaccttg gccagttggt ctcaaagtgt ggtacctgga tcagcagtat
6241 cactatcact tgggctagtt agagatccag attctggatc cataccccat acctactgaa
6301 ttagaaactc taggggatga atagtgggtg tctctgttgc taagtgcagc tgggcccagc
6361 cacctatttt aacaagccct cccagtgatt gtgatacata ctaaagtttg agaaccattg
6421 tactaggcca ttccagctga atctcaaaca gaaggcagta atgagagcct acaaatggga
6481 gggacctaaag tgccctaccta ctgcctaate gcaggtgcaa acacacaagg agtttgggtg
6541 gcttaagggtc agaggagtgt gtagggaggg atgtatgtgg aaggtaagat tcagggcaag
6601 ctaaaaatcc gatactgcaa cgttttccaa aatcccagaa ggcaaaactgt gcatgttcta
6661 ccctgaacca cccaagcaac actttctacc ttgccttatt ttttaattgga ttcactgtcc
6721 aaaatgcaga ggtttgcttt gctttttttt cagaagttcc aaacagcaac tttgagagca
6781 gtggggtgct tggcagctgt tctgtgtttt ccaggaatcc aactgagcat tgaaatctct
6841 catttgccga cttattttta taggaagcca attaaaaaaa aaaaagttt tcttatagta
6901 ttggaactac ttctaatttt aaaatgactt ttttgatgta ttttttggtt aatactatgt
6961 agtgtaatgt ataattgctc ttgtttattg cttttacaat catatttatt aaacagataa
7021 tgtctctaaa gtctttgcct caggatattt tttttttaat cctaaaccct tgggtgtcat
7081 tctaaatata gaagtgttgc atgtatagga tttcataaag gctaattgca taagaaagag
7141 taaacaccac aggccttgagg tttttggctg ttttttacta acaaggcaga atgtatgtac
7201 tacctgaatt ctacctgcat ttcaattaac tatacaatgt ctgtttatta aattactttg
7261 atttaaaaaa ta

//

Aug 28 2007 16:53:42